| Autor: |
Jorgensen, Sarah C. J., Hunter, Patrick K., Regenstreif, Lori, Sinai, Joanne, Malone, William J. |
| Předmět: |
|
| Zdroj: |
JACCP: Journal of the American College of Clinical Pharmacy; Sep2022, Vol. 5 Issue 9, p1005-1007, 3p |
| Abstrakt: |
7th version; https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7 English.pdf 2 Recommendation of the Council for Choices in Health Care in Finland (PALKO/COHERE Finland) Medical Treatment Methods for Dysphoria Related to Gender Variance in Minors. 22 Biggs M. Revisiting the effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria. 24 Klink D, Caris M, Heijboer A, van Trotsenburg M, Rotteveel J. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. The medical transition of children and adolescents with gender dysphoria remains highly debated and there is significant divergence in policy internationally.1-7 Mills and colleagues' review the interventions that comprise the "gender-affirmative" care pathway, an approach currently promoted by many medical organizations in North America.6-8 We strongly agree with the authors that pharmacists have a responsibility to "understand the evidence", and "place the well-being of the patient over any personal cultural beliefs."8 However, we think the use of evidence to support the authors' claim that gonadotropin releasing hormone (GnRH)-analogs are fully reversible and have been shown to improve mental health, requires critical appraisal. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text